Chronic Lymphocytic Leukemia
The treatment of patients with chronic lymphocytic leukemia (CLL) has undergone a dramatic transformation in the past year, with the approval of the novel oral agents ibrutinib (Imbruvica) and idelalisib (Zydelig).
Most Popular Right Now
Gary M. Kirsh, MD, Earl L. Walz, and Pamela Skurkay discuss the integration of the autologous cellular immunotherapy sipuleucel-T (Provenge) into clinical practice for men with asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. View Now